Bristol Myers Says EMA's CHMP Recommended Approval Of Opdivo Combination With Cisplatin, Gemcitabine For First-line Treatment Of Adult Patients With Unresectable Or Metastatic Urothelial Carcinoma
Portfolio Pulse from Benzinga Newsdesk
Bristol Myers announced that the EMA's CHMP has recommended the approval of Opdivo in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma. The European Commission will review the recommendation, with a final decision expected in June 2024.
April 26, 2024 | 11:04 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bristol Myers' Opdivo, combined with cisplatin and gemcitabine, received a positive recommendation from the EMA's CHMP for treating unresectable or metastatic urothelial carcinoma, awaiting the European Commission's final decision.
The positive recommendation from the EMA's CHMP for Opdivo in combination therapy is a significant step towards expanding its market in the EU. This news is likely to be viewed positively by investors, as approval can lead to increased sales and market share in a new treatment category. The anticipation of the European Commission's final decision may create positive sentiment around BMY's stock in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100